Adam Steensberg, Zealand Pharma CEO
Zealand rides obesity wave with $1B raise to advance amylin drug and look for a partner
Zealand Pharma is raising $1 billion to focus on its “crown jewel” — an amylin analog for weight loss — both to advance it into a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
